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The objective of this cross-sectional study was to assess differences in the control and treatment of modifiable cardiovascular risk
factors (CVRF: HbA1c, blood pressure [BP], LDL-cholesterol, body mass index, and smoking habit) according to gender and the
presence of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) in Catalonia, Spain.The study included
available data from electronic medical records for a total of 286,791 patients. After controlling for sex, age, diabetes duration, and
treatment received, bothmen and womenwith prior CVDhad worse cardiometabolic control than patients without previous CVD;
women with prior CVD had worse overall control of CVRFs than men except for smoking; and women without prior CVD were
only better than men at controlling smoking and BP, with no significant differences in glycemic control. Finally, although the
proportion of women treated with lipid-lowering medications was similar to (with prior CVD) or even higher (without CVD) than
men, LDL-cholesterol levels were remarkably uncontrolled in both women with and women without CVD. The results stress the
need to implement measures to better prevent and treat CVRF in the subgroup of diabetic women, specifically with more intensive
statin treatment in those with CVD.
1. Introduction
The prevalence rates of diabetes mellitus (DM) have signif-
icantly increased during the last years, accompanied by a
parallel rise in complications and deaths from the disease
[1, 2]. The worldwide prevalence in 2013 has been estimated
to be 8.3%, and it is expected to be about 1 adult in 10 by 2035,
which represents a substantial 55% increase [3, 4]. A recent
population-based survey conducted in Spain reported a
global prevalence of DMof 13.8% in adult subjects, and 43.5%
of them were unaware of their disease, thus corresponding to
a prevalence of unknown DM of 6% [5].
People with type 2 diabetes mellitus (T2DM) are at
increased risk of cardiovascular complications such as coro-
nary artery disease, stroke, or peripheral vascular disease [6,
7]. In turn, these complications are associated with increased
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morbidity and mortality and have a detrimental effect on
health-related quality of life [8]. Current available evidence
indicates that, in terms of risk reduction of cardiovascular
and microvascular complications, control of blood pressure
and lipid levels is more effective than glucose control [9–11].
Additionally, type 2 diabetic patients with clinical cardiovas-
cular disease (CVD) are at a higher risk of a recurrent cardio-
vascular event [12, 13]. However, several studies have shown
that, in clinical practice, secondary prevention strategies in
diabetic patients with CVD are associated with a suboptimal
cardiometabolic control [11, 14].
Systematic reviews of the literature have reported that
the excess relative risk of CVD attributable to diabetes is 2-
fold in men and 3- to 4-fold in women [15, 16], and this
has been further confirmed by several meta-analyses [17–19].
Some authors have postulated that diabetes prompts the loss
of the natural hormonal protection against CVD in women
[20, 21], but several factors that may explain this excess risk
in women relative to men have been identified so far [22–25],
and they mainly include a low risk perception by health care
providers [26]; an increased time to propermedical care from
the onset of symptoms; a lower predictive capability of certain
diagnostic tests (e.g., stress test); a differential drug response
among women to some medications such as aspirin [27] or
statins [28], which decreases their effectiveness; and worse
clinical outcomes after therapeutic procedures [29].
Cross-sectional studies have reported that the control of
cardiovascular risk factors (CVRF) is poorer among diabetic
women relative to diabetic men of the same age [30–32].
Moreover, the follow-up of the population in the National
Health and Nutrition Examination Surveys (NHANES) has
shown that, for the past years, there has been an overall
decline inmortality rates due toCVD, but not in the subgroup
of diabetic women [33].
On the other hand, studies derived from the analysis
of large databases have proven to be useful for evaluating
cardiometabolic control, associated risk factors, long-term
complications, and other clinically relevant aspects of T2DM
[34–37].
The aim of the present population-based study was to
assess differences in the degree of control and treatment of
modifiable CVRF according to gender and CVD in patients
with T2DM in Catalonia, Spain.
2. Materials and Methods
2.1. Design. This cross-sectional study includes all type 2
diabetes subjects visiting any of the 274 primary care centres
pertaining to the Catalan Health Institute (ICS) in Catalonia,
a northeastern region of Spain, which takes care of a popula-
tion of about 5.8 million patients (80% of the total population
for the region).
The data for the present study (eCONTROL) were
extracted from SIDIAP (Information System for the Devel-
opment of Research in Primary Care; SIDIAP) [38], a
database of electronic medical records started in 2006.
Methodological details of the study of diabetes mellitus using
this database have been described in previous publications
[36, 39]. Briefly, SIDIAP contains anonymized longitudinal
patient information obtained through use of specific software
(eCAP) implemented in all primary care centers in Catalonia
and includes sociodemographic characteristics, morbidity
(by means of International Classification of Diseases codes;
ICD-10), clinical and lifestyle variables, specialist referrals,
and results of laboratory tests and treatments based on
prescription- and pharmacy-invoicing data provided by the
CatSalut general database.
2.2. Data Extraction. Data from patients attended before July
1, 2009, aging 31 to 90 years, and with a diagnosis of type 2
diabetes (ICD-10 codes E11 or E14) were extracted from the
SIDIAP database [36]. Available variables (registered up to
the end of 2009) included age; gender; time since diagnosis;
estimated glomerular filtration rate (eGFR) using the Mod-
ified Diet in Renal Disease (MDRD) formula; standardized
glycated haemoglobin (HbA1c) values, using the most recent
value of the preceding 15 months; presence of cardiovascular
disease, including coronary artery disease (ICD-10 codes I20,
I21, I22, I23, or I24), stroke (ICD-10 codes I63, I64, G45,
or G46), and peripheral artery disease (ICD-10 code I73.9);
risk factors, including body mass index (BMI) (most recent
value in the last 24 months), cholesterol levels (total, low-
density lipoproteins or LDL-cholesterol, and high-density
lipoproteins or HDL-cholesterol; most recent value in the
last 15 months), blood pressure (BP) (systolic and diastolic
mean value in the last 12 months), smoking status (most
recent value); and data on prescribed glucose-lowering, lipid-
lowering, and antihypertensive and antithrombotic medica-
tions.
Diagnostic criteria for CVRF were HbA1c > 7%; hyper-
tension (blood pressure > 140/90mmHg); hypercholestero-
lemia (total cholesterol > 250mg/dL); hypertriglyceridemia
(triglycerides > 150mg/dL); obesity (BMI > 30 kg/m2); and
current or former smoking habit. Treatment goals for patients
with andwithout a history of CVDwere based on local guide-
lines [40, 41]; without CVD prevention: HbA1c ≤ 7%, BP ≤
140/90mmHg, and LDL-cholesterol ≤ 130mg/dL; with CVD
prevention: HbA1c ≤ 7%, BP ≤ 140/90mmHg, and LDL-cho-
lesterol ≤ 100mg/dL.
This study was approved by the Ethics Committee of the
Primary Health Care University Research Institute (IDIAP)
Jordi Gol.
2.3. Statistical Analysis. Descriptive analyses were summa-
rized by mean and standard deviation for continuous vari-
ables and percentages for categorical variables. Comparisons
by gender andpresence ofCVDwere performedwith Pearson
chi-square tests for categorical variables and analysis of
variance (ANOVA) for continuous variables. We applied
multilevel logistic regression models to identify the factors
associated with good cardiometabolic control of CVRFs.
Only those variables with a statistically significant effect
(𝑃 < 0.05) in the univariate analyses were retained for
the multivariate model. Analyses were performed stratifying
according to the presence of CVD, and odds ratios (OR) and
95% confidence intervals (95%CI) were adjusted for gender,
diabetes duration, and treatment as confounding variables.
Statistical calculations were performed using StataCorp 2009
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(Stata Statistical Software: Release 11. College Station, TX:
StataCorp, LP).
3. Results
The study included data from a total of 286,791 patients with
T2DM (153,987 men and 132,804 women). Overall, 18.4% of
the patients (𝑁 = 52,665) had a previous history of any CVD,
which was more frequently reported among men (22.3%
versus 13.8%).
In the overall population, all studied variables showed sig-
nificant differences betweenmen andwomen;womenwere in
average older than men, had a longer duration of the disease,
and had slightly worse cardiometabolic control than men,
with higher blood pressure levels (mean 137.5/76.2mmHg
versus 136.9/76.6mmHg; 𝑃 < 0.005), higher LDL-cholesterol
levels (mean 115.6mg/dL versus 109.7mg/dL; 𝑃 < 0.005),
and higher average BMI (mean 30.5 versus 28.8; 𝑃 < 0.005),
but slightly better control of the percentage of HbA1c than
men (7.1% versus 7.2%; 𝑃 < 0.005) (Table 1). Moreover,
triglyceride levels were lower in women (mean 153.5mg/dL
versus 158.5mg/dL; 𝑃 < 0.005), and there were far more
nonsmokers among diabetic women (88% versus 43.5%; 𝑃 <
0.005).
3.1. Cardiometabolic Control of T2DMandDegree of Control of
CVRF according to History of CVD and Gender. The stratified
analysis according to history of CVD showed that men with
prior CVD had significantly better control of BP, weight, lipid
profile, and smoking than men without a history of CVD
(all variables 𝑃 < 0.001) (Table 1). Additionally, there were
no clinically significant differences with regard to glycemic
control between the groups (𝑃 = 0.058). However, this
pattern was strikingly different among women: those with
previous CVD had significantly higher HbA1c (7.2% versus
7.1%; 𝑃 = 0.003), systolic BP (mean 138mmHg versus
137.5mmHg;𝑃 < 0.001), and triglyceride values (156.3mg/dL
versus 153.1mg/dL; 𝑃 < 0.001) than women without a history
of CVD.
When considering the adequate treatment goals of
CVRFs by gender, women showed worse overall control than
men (𝑃 < 0.005 for all variables except for smoking); this
was seen both in subjects with no previous CVD and in those
with history of any CVD (𝑃 < 0.001 for all studied variables)
(Table 1 and Figure 1).The greatest differences comparedwith
men were seen in the levels of LDL-cholesterol and in weight,
while differences in BP were less evident, and the percentage
of patients with HbA1c ≤ 7% was slightly higher among
women without CVD (56.8% versus 56%, 𝑃 < 0.05) and
lower in women with CVD (54.6% versus 55%, 𝑃 < 0.05). In
accordance, the degree of composite control ofCVRFs, that is,
simultaneously taking into account hyperglycemia (HbA1C≤
7%, BP ≤ 140/90mmHg) and LDL-cholesterol levels (LDL-
cholesterol ≤ 130mg/dL in patients without previous CVD
and ≤100mg/dL in those with prior CVD), was significantly
worse among women: 25.1% of women without CVD were in
good control compared to 27% ofmen, and among those with
priorCVD, 17.7%ofwomenhad anoptimal composite control
versus 22.8% of men (𝑃 < 0.005 in both cases). Moreover,
the proportion of patients with good composite control of
CVRFs was lower among those with prior CVD, and this
was true for both men and women: 17.7% of women with
prior CVD were in good control versus 21.5% without CVD
(𝑃 < 0.001), and 22.8% of men with prior CVD were in good
control versus 27% without CV (𝑃 < 0.001).
3.2. Multivariate Analysis of Good CVRF Control according
to Gender and CVD. After adjusting for gender (woman),
age, diabetes duration, and treatment received, multivariate
analysis showed that men in secondary prevention after CVD
had better control of all risk parameters except for smoking.
In the case of prevention of CVD, women still had better
control over smoking than men, but also better control of
their BP, whilst there were no clinically significant differences
in glycemic control between genders (Table 2), and women
remained worse than men at controlling weight and LDL-
cholesterol levels.
3.3. Degree of CVRF Control in Different CVDs. Study of
the different macrovascular complications, specifically coro-
nary heart disease (CHD), stroke, or peripheral arterial
disease (PAD), showed that the proportion of women with
good control of target CVRFs, namely, HbA1c ≤ 7%, BP ≤
140/90mmHg, and BMI ≤ 30Kg/m2, and also lipid profiles
in subjects with or without prior CVD was lower than men
irrespective of the type of CVD (𝑃 < 0.001 in all cases)
(Table 3).
3.4. Treatment of CVRFs in Patients with and without CVD
according to Gender. We further studied whether treatment
for the different CVRFs differed between genders in the
presence/absence of prior CVD (Table 4). Among the subset
of patients without a history of CVD, women had higher
rates of prescribed glucose-lowering, antihypertensive, and
lipid-lowering drugs than men (75% versus 73.3%, 70.8%
versus 59.9%, and 47.6% versus 43.1%, resp.) and similar use
of antiplatelet agents (27.6% versus 28.3%). However, in the
subgroup of patients with a history of CVD, differences in
the use or intensity of glucose-lowering and lipid-lowering
treatments were not clinically relevant between genders, but
women used less antiplatelet agents (71.8% versus 77.5%)
and more antihypertensive agents (88.4% versus 86.4%) than
men. Of note was that oral glucose-lowering agents in mono-
or combined therapy were less often prescribed to women
than to men in favor of a greater use of insulin therapy, either
alone or combined with oral glucose-lowering drugs.
4. Discussion
Gender differences among the diabetic population include
disparities in adherence to treatment [42], in control of
cardiometabolic parameters and risk of CVD [30, 31, 43], and
also in the therapeutic management of cardiovascular risk
factors [25, 44, 45].
Theprevalence rates of T2DMandCVD in our studywere
higher amongmen,which is in linewith previous population-
based studies [30, 46–48], although rates vary depending on
the age range, country, and definition of CVD.
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Table 2: Multivariate analysis on the degree of control of CVRFs stratified according to the presence of CVD.
CVD No CVD
ORa (95% CI)∗ 𝑃 value ORa (95% CI)∗ 𝑃 value
HbA1c ≤ 7% 0.95 (0.91–1.00) 0.041 1.01 (0.99–1.03) 0.23
PA ≤ 140/90mmHg 0.879 (0.84–0.92) <0.001 1.082 (1.06–1.13) <0.001
LDL-cholesterol
≤130mg/dL (CVD) 0.67 (0.64–0.70) <0.001 0.74 (0.72–0.76) <0.001
≤100mg/dL (no CVD)
BMI ≤ 30Kg/m2 0.50 (0.48–0.52) <0.001 0.53 (0.52–0.54) <0.001
Nonsmoker 4.20 (3.86–4.58) <0.001 4.01 (3.39–4.13) <0.001
BMI: body mass index; BP: blood pressure; CVD: cardiovascular disease; OR: odds ratio.
∗ORa: odds ratio adjusted by age, diabetes duration, treatment received, and sex (women).
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Figure 1: Percentage of patients with T2DM and good control of CVRF by gender and history of CVD (all variables showed significant
differences between sexes (𝑃 < 0.005) and between CVD and no CVD in both men and women (𝑃 < 0.001), except for HbA1c: 𝑃 = 0.058 in
men and 𝑃 = 0.003 in women. BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease).
The results of the study showed that there were signif-
icant gender differences in the control of T2DM and CVD
individual risk factors. Namely, compared with men, women
were on average older and had a longer duration of disease,
and apart from less frequently being smokers than men, they
had poorer control of hypertension, LDL-cholesterol levels,
and BMI. This profile of worse control of CVRFs has been
consistently reported before in previous surveys conducted
in Spain and in other countries [30–32, 39, 43, 49–52], but
the present study is the largest one ever performed in real-
life clinical practice. Moreover, the proportion of women
who achieved the target of stipulated recommendations to
control the risk of CVD in our study was lower than men
except for glycemic control, and the composite control of
multiple risk outcomes (Hb1Ac, BP, and LDL-cholesterol
simultaneously) was also poorer amongwomen.These results
are also in agreement with the above mentioned studies
and with results from studies specifically assessing gender
differences in composite risk factors in T2DM [43, 53], which
have found that women are approximately 3 times less likely
to achieve combined cardiometabolic control than men [43].
There are few reports assessing the control of CVRFs in
T2DM according to gender as well as for the presence of
prior CVD, and the present study is the first one conducted
in a Spanish population. Our analysis stratifying by presence
of prior CVD showed that both men and women with
CVD in general had poorer control of CVRFs than those
without. As for the degree of control of modifiable CVRFs,
multivariate analysis showed that women with prior CVD
were less likely to achieve their therapeutic targets than men
for all parameters except for smoking. Women without CVD
achieved the recommendedHbA1c target as optimally asmen
andwere better at controlling BP and smoking but againmore
frequently did not achieve recommended therapeutic targets
for obesity and LDL-cholesterol. Our results on patients
with prior CVD are in agreement with a previous cross-
sectional study conducted in Germany, which found that
women were more likely to have uncontrolled systolic BP,
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LDL-cholesterol, and HbA1c levels [25]; similarly, another
cross-sectional analysis conducted in the US found that
women were more liable to have suboptimal control of
systolic BP and LDL-cholesterol but found no differences in
glycemic control relative to men [45]. As for patients without
prior CVD, the US study found no significant differences in
the degree of control of any studied modifiable CVRF [45],
and the German study only found a higher probability of
women having uncontrolled LDL-cholesterol relative to men
[25], which is in agreement with our results, although we also
found that women had even better control of BP than men.
Unfortunately, our results on smoking and BMI cannot be
compared with these 2 studies, since both of them included
these 2 risk factors as confounding covariates in their analysis.
There is compelling evidence in Spain and other countries
that women receive less health care attention not only for the
treatment of their T2DM [54], but also for the prevention
and treatment of associated CV complications [14, 19, 25, 26,
30, 44, 45], as women both with and without CVD receive
less lipid-lowering and antithrombotic therapy thanmen [29,
47, 55, 56]. Studies stratifying by gender and comorbid CVD
are scarce but concur that women are less intensively treated
with lipid-lowering drugs than men, in patients both with
and without prior CVD, while findings on gender disparities
according to prior CVD regarding the use or intensity of
treatment with antihypertensive or glucose-lowering drugs
are inconsistent across reports [25, 45, 47]. Differences
between studies may be due to genetic or ethnic differences,
geographical variations in access to available health care
resources, different ambulatory physician practices between
countries, and disparities in the economic barriers to care
due to the type of insurance (public or private) paying for the
treatment.
When we assessed whether there were gender disparities
in the management of modifiable CVRF in T2DM patients
according to a history of CVD, we found that women were
more likely to be treated with antihypertensive drugs and
less likely to take antiplatelet drugs than men irrespective
of having a history of CVD, while glucose- and lipid-
lowering treatment varied according to the absence/presence
of prior CVD: the proportion of women with CVD taking
glucose and/or lipid-lowering medications was similar to
men, but women without CVD took more glucose and/or
lipid-lowering drugs than men. However, while the degree
of achieved glycemic control was similar between women
with and without previous CVD, lipid levels were remarkably
uncontrolled in both cases and more pronounced in women
with prior CVD. This is of concern if we take into account
that a history ofCVD is an independent factor associatedwith
higher morbidity and mortality and that the 4-year survival
rate of women with prior CVD is lower than in women
without a history of CVD [30].Moreover, the fact that women
without prior CVD did not achieve adequate control of lipid
levels, in spite of being more likely to be treated with lipid-
lowering medications than men, could be related to the use
of less intensive therapy or to a differential response to statins
relative to men, although this is controversial in the case of
primary prevention [57, 58]. With regard to the degree of
control of BP, we observed that women without CVD had
similar control to men, in spite of higher levels of treatment
with antihypertensive drugs, while women with CVD still
had uncontrolled BP relative to men although they were
treated in a comparable proportion, an observation that has
been previously reported [29]. This is also of concern if we
consider that women have a higher lifetime risk of stroke than
men, in part because they have a longer life expectancy and
because the risk of stroke increases with age [59], therefore,
underlining the need for more intensive or proper control of
BP. Taken together, our results show that the treatment and
control of the 2 parameters thatmost effectively preventCVD,
namely, BP and lipid levels, remain a challenge (particularly
LDL-cholesterol levels) in the case of womenwith T2DMand
a history of CVD.
Strengths of the present study include the use of registries
coming from primary care medical records, which allows
the collection of a large volume of patients’ real-life clinical
practice data.However, there are some limitations that should
be acknowledged and considered when interpreting the
results of this study. Firstly, inherent to any cross-sectional
design, no causal associations or conclusion on trends in
treatment can be drawn, and the retrospective design is
subject to biases concerning the lack of data recording for
some of the studied variables (e.g., 25% of patients did not
have corresponding HbA1c values for the previous year).
Secondly, the studied cohort is representative of a specific
territory in Spain and may not necessarily reflect standards
of care in other territories. Thirdly, information on treated
(and the specific therapeutic agents prescribed) anduntreated
patients was based on drugs obtained at the pharmacy, and
we were not able to assess medication adherence factors.
Finally, we had no data to assess factors known to differ by
gender in T2DM that may influence disease outcomes, such
as diabetes knowledge, self-management practices, lifestyle
related factors, socioeconomic status, education, or social
support [51].
5. Conclusions
The results of the study confirm that Spanish women with
T2DM have suboptimal control of CVRFs; they also show
that compared with men women with CVD were less likely
to achieve therapeutic goals for BMI, BP, LDH-cholesterol,
and HbA1c and that those without a history of CVD were
also less likely to achieve BMI and LDL-cholesterol rec-
ommended goals. Furthermore, although the proportion of
women treated with lipid-lowering medications was similar
to or even higher than men, LDL-cholesterol levels were
remarkably uncontrolled in both women with and without
CVD, and women with CVD still had uncontrolled BP
relative to men in spite of being treated with antihypertensive
drugs in a comparable proportion of cases. The observed
differences have clinical implications that warrant further
investigation through studies specifically designed to assess
gender differences in the control of modifiable CVRF and
further stress the need to implement measures to better
prevent and treat this subgroup of diabetic women. Actions
should include not only targeted awareness programs for
health professionals, but also the implementation of specific
International Journal of Endocrinology 9
educational programs aimed at improving self-awareness and
self-care in women with T2DM.
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